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ABSTRACT
Melphalan is a cytotoxic chemotherapy used to treat patients with multiple myeloma 
(MM). Bone resorption by osteoclasts, by remodeling the bone surface, can reactivate 
dormant MM cells held in the endosteal niche to promote tumor development. Dormant 
MM cells can be reactivated after melphalan treatment; however, it is unclear whether 
melphalan treatment increases osteoclast formation to modify the endosteal niche.
Melphalan treatment of mice for 14 days decreased bone volume and the endosteal 
bone surface, and this was associated with increases in osteoclast numbers. Bone 
marrow cells (BMC) from melphalan-treated mice formed more osteoclasts than BMCs 
from vehicle-treated mice, suggesting that osteoclast progenitors were increased. 
Melphalan also increased osteoclast formation in BMCs and RAW264.7 cells in vitro, 
which was prevented with the cell stress response (CSR) inhibitor KNK437. Melphalan 
also increased expression of the osteoclast regulator the microphthalmia-associated 
transcription factor (MITF), but not nuclear factor of activated T cells 1 (NFATc1). 
Melphalan increased expression of MITF-dependent cell fusion factors, dendritic cell-
specific transmembrane protein (Dc-stamp) and osteoclast-stimulatory transmembrane 
protein (Oc-stamp) and increased cell fusion. Expression of osteoclast stimulator 
receptor activator of NFκB ligand (RANKL) was unaffected by melphalan treatment.
These data suggest that melphalan stimulates osteoclast formation by increasing 
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osteoclast progenitor recruitment and differentiation in a CSR-dependent manner. 
Melphalan-induced osteoclast formation is associated with bone loss and reduced endosteal 
bone surface. As well as affecting bone structure this may contribute to dormant tumor cell 
activation, which has implications for how melphalan is used to treat patients with MM.
INTRODUCTION
The alkylating drug melphalan in combination with 
corticosteroids has been the first-line therapy for patients 
with multiple myeloma (MM), an incurable plasma 
cell cancer [1], for many decades. MM is the second 
most common hematological cancer and its progression 
results in immunodeficiency, renal failure and osteolytic 
bone disease [2, 3]. Whilst novel targeted agents such 
as thalidomide, bortezomib and lenalidomide have been 
introduced, melphalan remains a commonly used therapy 
for non-transplant patients and is also used in high-dose 
therapy associated with autologous stem cell transplant 
[1]. Although these treatments improve survival, patients 
typically undergo relapse and the disease progresses. Thus, 
MM remains largely incurable.
In the early stages of MM development, as with 
other cancers that metastasize to bone, colonizing cancer 
cells localize to specialized niches where they reside in a 
dormant or low proliferating state for long periods of time 
[4]. Recent studies have shown that in MM cells of the 
osteoblast lineage play an important role in the endosteal 
niche and have the capacity to hold MM in a dormant 
state for a prolonged period [5, 6]. In this state, dormant 
cells are resistant to conventional chemotherapies, 
including melphalan, that target proliferating tumor cells 
and are available to re-populate the tumor following 
treatment withdrawal [4, 5]. We have recently shown 
that osteoclasts, the cells responsible for normal bone 
resorption, can remodel the endosteal niche and re-activate 
dormant tumor cells [5]. Osteoclasts therefore play a role 
in both controlling the re-activation of dormant MM cells 
and in mediating the development of osteolytic MM bone 
disease.
Osteoclasts are multinucleated bone-resorbing 
cells derived from hematopoietic progenitors in the bone 
marrow under the control of RANKL produced by local 
osteoblast lineage cells [7]. RANKL can bind its cognate 
receptor RANK and activate signaling molecules needed 
for osteoclast differentiation, including the transcription 
factors NFκΒ, NFATc1 and MITF. MM cells also produce 
RANKL and induce its production in the local bone 
microenvironment, thereby increasing osteoclastic bone 
resorption and promoting bone loss [8-12]. This tumor-
associated bone loss can be mitigated by anti-osteoclastic 
therapies such as bisphosphonates, or anti-tumor therapies 
such as melphalan. However, while melphalan treatment 
in vivo kills proliferating tumor cells, it also results in 
activation of dormant myeloma cells [5], which may have 
implications for disease progression. This observation 
might be explained by increased osteoclast resorption 
and if so would have implications for both tumor relapse 
and the risk of bone fractures. However, the effect of 
melphalan treatment on osteoclasts is unknown. Indeed, 
given the toxic effects of melphalan on bone marrow 
cell populations, which contain osteoclast progenitors, 
a decrease in osteoclastic resorption would be expected. 
However, given the significant implications of pro-
osteoclastic effects we investigated the effect of melphalan 
treatment on the endosteal niche in bone. We found that 
melphalan treatment causes rapid bone loss in mice and 
strongly enhances osteoclast formation through several 
mechanisms.
RESULTS
Melphalan increases osteoclast numbers and 
decreases bone volume in vivo
8-week old male mice were treated with melphalan 
for 3, 7 and 14 days. Microcomputed tomography 
(microCT) analysis of the metaphyseal region of the distal 
femur showed melphalan had little or no significant effects 
at days 3 and 7, but after 14 days treated mice showed 
reduced trabecular bone volume (51%) and bone surface 
(43%) compared to controls (Figure 1A, 1B, 1C). This 
reduced bone mass was associated with lower trabecular 
number (46%, Figure 1D) and higher trabecular separation 
(33%, Figure 1E) with unchanged trabecular thickness 
(Figure 1F). Melphalan also significantly reduced trabecular 
bone volume and surface at the growth plate and primary 
spongiosa at day 14 (Supplementary Figure 1A-1C). 
This was associated with a decrease in trabecular number 
(Supplementary Figure 1D) and increase in trabecular 
separation (Supplementary Figure 1E) with trabecular 
thickness unchanged (Supplementary Figure 1F). 
Melphalan did not affect the cortical bone (data not shown).
Histomorphometric analysis of trabecular bone 
in the distal femoral bone metaphysis demonstrated 
spatial differences in osteoclast response to melphalan 
treatment. The number of osteoclasts and the osteoclast 
surface per bone surface within the trabecular bone (the 
secondary spongiosa) were increased at day 3 compared 
with vehicle-treated mice (Figure 1G). This was not seen 
at later time points (Figure 1G, ii and G, iii). In contrast, 
within the growth plate and primary spongiosa, we 
observed an increase in the number of osteoclasts and 
osteoclast surface per bone surface after 7 and 14 days 
of melphalan treatment (Figure 1H). This was consistent 
with the significant reduction in trabecular bone volume 
(Figure 1A–1F) and primary spongiosa (Supplementary 
Figure 1) observed at day 14.
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Interestingly, a transient increase in trabecular 
bone volume and thickness was observed after 3 days 
of melphalan treatment (Figure 1B, 1F). This is likely 
explained by the increase in osteoblast numbers at this time-
point (Supplementary Figure 2A) reflecting the coupling 
to increased bone resorption at this time [13]. Osteoblast 
numbers were otherwise unaffected at later time-points. 
Melphalan treatment increases osteoclast 
progenitor number in vivo
Bone marrow cell populations are altered by 
cytotoxic agent treatment, we therefore examined the 
effect of melphalan treatment on bone marrow cells by 
flow cytometry. Melphalan did not affect total cell numbers 
Figure 1: Melphalan treatment increases osteoclast numbers in bone and reduces bone mass in mice. (A) Three-
dimensional reconstructions of microCT scans of representative femora of mice treated with vehicle or melphalan for 3 and 14 days as 
indicated; regions of interest for analysis are indicated by white or red box; scale bar = 1mm. (B-F) MicroCT analysis of the trabecular 
bone in the secondary spongiosa of the femora of mice treated with vehicle (Veh.) or melphalan (Mel.) for 3, 7 and 14 days, including (B) 
trabecular bone volume/tissue volume (BV/TV) (C) trabecular bone surface area/tissue volume (BS/TV), (D) trabecular number (Tb.N), 
(E) trabecular separation (Tb.Sp) and (F) trabecular thickness (Tb.Th). (G) Histological analysis of osteoclasts in the femoral secondary 
spongiosa showing (i) hematoxylin stained histological sections of the femora with arrowheads identifying TRAP+ osteoclasts (red color) 
on trabecular bone surfaces (scale bar = 100μm; high power view of boxed area shown bottom left) and quantification by histomorphometry 
of (ii) osteoclast numbers and (iii) bone surface covered by osteoclasts. (H) Histological analysis of osteoclasts in the femoral growth 
plate and primary spongiosa showing (i) hematoxylin stained sections of the femora with arrowheads identifying TRAP+ osteoclasts (GP 
= growth plate, scale bar = 50μm); and quantification of (ii) osteoclast numbers and (iii) bone surface covered by osteoclasts. Numerical 
data presented as individual data points with indicated mean ± SD and represent 4-8 mice per group. *p<0.05; **p<0.01; ***p<0.001 using 
ANOVA/Dunnett’s post hoc test or (for two-way comparisons) Student’s t-test.
Oncotarget68050www.impactjournals.com/oncotarget
(Figure 2A, Supplementary Figure 3A) although B-cells 
were decreased by melphalan treatment (Supplementary 
Figure 3B), consistent with its effects on myeloma 
cells. The numbers of granulocytes were increased 
(Supplementary Figure 3B) as well as dendritic cells 
(Supplementary Figure 3C). Total monocyte/macrophage 
lineage cell numbers (CD115+) were unchanged by 
melphalan (Figure 2B); immature macrophage populations 
(CD11b- GR1- CD115+) were also unchanged (Figure 2C 
left), but mature osteoclast/macrophage lineage (CD11b+ 
GR1- CD115+) cells were significantly increased (Figure 
2C right). To investigate whether melphalan treatment 
affects osteoclast progenitor numbers in the bone marrow, 
we measured osteoclast formation from BMCs in vitro, 
when stimulated with M-CSF and RANKL. Indeed, 
BMCs from melphalan-treated mice yielded much greater 
osteoclast numbers than those from vehicle-treated mice 
(Figure 2D). No osteoclast formation was observed in the 
absence of RANKL.
Melphalan treatment directly enhances 
osteoclast formation in vitro and increases levels 
of both MITF protein and MITF-dependent 
expression of cell fusion-related genes
To determine whether melphalan affects osteoclast 
progenitors as they undergo differentiation, RANKL- and 
M-CSF-treated BMCs were cultured with melphalan (or 
vehicle) for 6 days. Melphalan dose dependently increased 
osteoclast formation (Figure 3A). In RANKL-stimulated 
RAW264.7 cell cultures, melphalan similarly enhanced 
osteoclast formation with maximal effects at 2 μM (Figure 
3B). Higher concentrations of melphalan caused extensive 
cell death (data not shown). Osteoblast mineralization was 
unaffected in vitro by melphalan treatment (Supplementary 
Figure 2B).
To investigate the mechanisms that underlie 
melphalan enhancement of osteoclast formation, we 
assessed its effects on key RANKL-stimulated pathways 
required for differentiation, including NFκB, NFATc1 
and MITF (Figure 3C). NF-κB- and NFAT-RAW reporter 
cells responded strongly to RANKL stimulation but not to 
melphalan treatment (Figure 3D, 3E), nor did melphalan 
enhance the RANKL-elicited signals. Western blot studies 
also confirmed that melphalan had no effect on NFATc1 
levels (Figure 3F), indicating NFκB and NFATc1 nuclear 
factors are unlikely to mediate melphalan effects on 
osteoclast formation. In contrast, MITF protein levels in 
bone marrow macrophages (BMMs) and RAW264.7 cells 
showed an increase with melphalan treatment at 2 and 5 
μM (Figure 3G), suggesting that the enhanced RANKL-
elicited osteoclast formation occurs at least partly through 
MITF-dependent pathways.
To examine this, the effect of melphalan on 
osteoclast-associated (and RANKL/MITF dependent) 
gene expression was measured in RAW264.7 cells. After 
Figure 2: Melphalan treatment in vivo results in altered osteoclast progenitor numbers in the femoral bone marrow. 
(A-C) Flow cytometry analysis of bone marrow cells from mice treated with vehicle (Veh.) or melphalan (Mel.) for 3 days. (A) Total live 
cells were analyzed as a proportion of all cells. Live cells were then analyzed to determine relative numbers of (B) monocytes/macrophages 
(CD115+), (C) immature macrophage subpopulations (CD11b-/GR1-/CD115+) and more mature macrophages (CD11b+/Gr1-/CD115+). (D) 
Bone marrow cells from mice treated with vehicle or melphalan were assessed for osteoclast formation ex vivo in the presence of 25ng/
ml M-CSF in combination with 0, 10 and 20ng/ml RANKL for 6 days; scale bar = 50μm. For graphs in (B) and (C) data is presented as 
individual data points with indicated mean ± SD. *p<0.05; **p<0.01; ***p<0.001 using Student’s t test (n = 8). Graph in (D) shows mean 
and S.E.M. using ANOVA/Dunnett’s post hoc test (n = 8).
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Figure 3: Melphalan treatment in vitro enhances osteoclast formation and increases MITF but not NFATc1 levels 
in osteoclast progenitor populations. (A) Histochemical analysis of TRAP+ multinucleated cells (MNCs) of bone marrow cells 
cultured in 20ng/ml RANKL and 25ng/ml M-CSF in combination with doses of melphalan or vehicle for 6 days. (i) Photomicrographs 
showing histochemical staining of TRAP+ MNCs indicated by arrowheads (boxed area shown at higher magnification in inset image) and 
(ii) quantitative dose response data from cultures (n = 4). Scale bars = 50 μm. (B) Histochemical analysis of TRAP+ MNCs of RAW264.7 
cells cultured in 20ng/ml RANKL with melphalan or vehicle for 6 days (i) Photomicrographs showing histochemical staining of TRAP+ 
MNCs indicated by arrowheads and (ii) quantitative dose response data from cultures (n = 4). Scale bars = 50 μm. (C) Simplified diagram 
of transcription factor induction cascade induced by RANKL/RANK binding causing increased levels of active NFkB, NFATc1 and MITF. 
Note many important factors in this cascade (e.g., AP-1 and p38) are omitted for clarity. RANKL and melphalan treatment for 24 h on 
the induction of signals in (D) NFkB-RAW and (E) NFAT-RAW reporter cells, showing induction by RANKL but not by melphalan. (F) 
Western blot analysis of NFATc1 protein levels in RAW264.7 cells treated with RANKL, vehicle or melphalan for 48 h. (G) Western 
blot analysis of MITF protein levels of bone marrow macrophages (BMMs) and RAW264.7 cells treated with vehicle or melphalan in 
the absence of RANKL for 48 h. (H) qRT-PCR-analysis of osteoclast-associated mRNA levels in RAW264.7 cells treated with vehicle 
or melphalan in the absence of RANKL for 24 h. (I) Histochemical analysis of MNCs formed in RAW264.7 cells treated with vehicle or 
melphalan in the absence of RANKL for 6 days. (i) Photomicrographs of MNCs as indicated by arrowheads and (ii) quantification of the 
MNCs. Scale bars = 50μm. (J) Quantification of TRAP+ MNCs in RAW264.7 cells treated with 2μM melphalan in the presence of RANKL 
for 6 days. In photomicrographs (A, B and I) the boxed areas shown at higher magnification in inset images. Quantitative data from in vitro 
experiments presented as mean ± S.E.M. from 4 independent experiments. *p<0.05, **p<0.01, ***p<0.001, using ANOVA/Dunnett’s post 
hoc test.
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melphalan treatment (2 and 5 μM) for 24 hours, mRNA 
was extracted and analyzed by quantitative RT-PCR (qRT-
PCR). Expression of tartrate resistant acid phosphatase 
(TRAP; Acp5) mRNA was increased by melphalan 
treatment 1.5 fold (Figure 3H) as was that of osteoclast 
cell fusion factors Dc-stamp and Oc-stamp, although not 
vATPase V0d2 subunit (Atp6v0d2) (Figure 3H). mRNA 
expression of Cathepsin-K (Ctsk) and Nfatc1 were not 
affected. The effects on Dc-stamp and Oc-stamp mRNA 
by melphalan implicated cell fusion effects, which we 
investigated with RAW264.7 cells. These (but not BMM 
or bone marrow cells) have a natural propensity to fuse 
in culture to form macrophage polykaryons, even in the 
absence of RANKL. Melphalan treatment increased 
multinucleated cell (MNC) numbers (and nuclear number) 
in RAW264.7 cultures in the absence of RANKL (Figure 
3I). In the presence of RANKL, melphalan also markedly 
increased the numbers of large osteoclasts with high 
nuclear numbers (Figure 3J).
Melphalan actions on osteoclasts show cell stress 
dependence
Increased osteoclast differentiation and higher MITF 
levels elicited by melphalan is consistent with cell stress 
response (CSR)-induced effects on osteoclasts [14, 15]. 
Indeed, melphalan treatment increased protein levels of the 
CSR marker heat shock protein 70 (Hsp70) (Figure 4A, l 
eft), an action reduced by co-administration of the HSP 
inhibitor KNK437 (Figure 4A, right). Consistent with 
this and our earlier observations [14], melphalan effects 
on osteoclast formation in RAW264.7 cells were greatly 
reduced by KNK437 (Figure 4B), which, was also seen in 
BMC cultures (Figure 4C). Notably, KNK437 treatment 
Figure 4: Enhancement of osteoclast formation caused by melphalan is reduced by HSP inhibitor KNK437. (A) Western 
blot analysis of Hsp70 protein levels in RAW264.7 cells treated with melphalan in the absence and presence of HSP inhibitor KNK437 for 
48 h. (B) Histochemical analysis of TRAP+ MNCs in RAW264.7 cells treated with RANKL and melphalan in the absence and presence 
of KNK437 for 6 days. Scale bars = 50 μm (i) Photomicrographs of TRAP+ MNCs as indicated by arrowheads and (ii) quantitative data 
showing the effects of KNK437 on TRAP+ MNCs formed in RANKL and melphalan and RANKL treated cultures of RAW264.7 cells. (C) 
Histochemical analysis of TRAP+ MNCs in bone marrow cells treated with M-CSF, RANKL and melphalan in the absence and presence 
of KNK437 for 6 days. (i)Photomicrographs of TRAP+ MNCs as indicated by arrowheads and (ii) quantitative data showing the effects 
of KNK437 on TRAP+ MNCs formed in RANKL and melphalan treated cultures. In photomicrographs (B and C) the boxed areas shown 
at higher magnification in inset images. Scale bars = 50 μm. Data presented as mean ±S.E.M. from 4 independent experiments. *p<0.05, 
**p<0.01, ***p<0.001 relative to vehicle treated controls, using ANOVA/Dunnett’s post hoc test.
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itself did not affect RANKL-dependent osteoclast 
formation in the absence of melphalan.
Melphalan effects on local RANKL expression 
are weak or absent
To address the possibility that melphalan may 
affect osteoclast activity in vivo by stimulating local 
levels of RANKL, we assessed melphalan effects on 
mRNA expression of RANKL and OPG (the secreted 
decoy receptor of RANKL) in bone marrow stromal 
cells (BMSCs). These populations contain mature and 
immature osteoblasts and related cells that strongly 
express RANKL in response to osteolytic stimuli such 
as 1,25-D3. Indeed,  1,25-D3 treatment increased BMSC 
RANKL mRNA levels 36 fold and decreased OPG mRNA 
by over 90% (Figure 5A). Melphalan treatment increased 
RANKL and decreased OPG mRNA levels but only very 
modestly in comparison (Figure 5B). We therefore tested 
whether melphalan-treated BMC/BMSC co-cultures 
support osteoclast formation. Positive controls (1,25-D3 
stimulation for 7 days) showed large-scale osteoclast 
formation in these co-cultures, but melphalan treatment 
resulted in only occasional TRAP+ mononuclear cells 
(Figure 5C) and no osteoclast formation. Furthermore, 
no increase in RANKL mRNA was observed in bones 
of mice treated with melphalan over 3 days (Figure 5D). 
This suggests that melphalan affects osteoclast formation 
mainly through its effect on osteoclast-intrinsic factors 
rather than increasing RANKL levels.
DISCUSSION
In this study we have found strong evidence that 
melphalan therapy modifies the bone microenvironment 
by stimulating the formation of osteoclasts. Treatment of 
tumor-naïve mice with melphalan caused loss of more 
than half the trabecular bone over two weeks [5]. This 
was mediated by an increase in osteoclast numbers caused 
by melphalan treatment. Although some cytotoxic drugs 
affect bone formation by suppressing gonadal hormone 
levels [16], melphalan did not reduce osteoblast numbers. 
Furthermore, the bone loss was associated with lower 
trabecular number (rather than trabecular thickness), 
which is a hallmark of osteoclast-mediated bone loss. 
Whilst these studies were performed in young mice and 
myeloma typically occurs in older individuals, these data 
provide important evidence that melphalan treatment 
increases osteoclast formation and causes bone loss.
Melphalan treatment strongly increased osteoclast 
numbers on mature trabecular bone surface by day 3 
(Figure 1G), which is consistent with the pro-osteoclastic 
effects of melphalan seen in vitro and suggests melphalan 
is a potentially osteolytic stimulus with the potential 
Figure 5: Melphalan increases RANKL expression in primary bone marrow stromal cells (BMSCs) in vitro. qRT-PCR 
analysis of RANKL and OPG mRNA in BMSC treated with (A) 1,25-D3 or (B) melphalan for 24 h (n = 3).(C) Histochemical analysis of 
TRAP+ MNCs in co-cultures of fresh bone marrow cells and in vitro expanded BMSCs treated with vehicle, 1,25-D3 or melphalan for 6 
days (n = 3). Scale bars = 50μm. (D) RANKL and OPG mRNA levels were determined in whole bones (tibiae) of mice treated for 3 days 
with melphalan or vehicle (n = 8). Data presented as mean ±S.E.M. *p<0.05, **p<0.01, ***p<0.001 relative to vehicle treated controls, 
using ANOVA/Dunnett’s post hoc test or t-test for 2-way comparison.
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to disrupt cell surface niches such as those containing 
dormant tumor cells [5]. Whilst osteoclast numbers were 
not increased in this region at later time points they were 
elevated in the growth plate region, which explains the 
decrease in bone surface and bone volume.
Our in vitro investigations found strong mechanistic 
evidence that melphalan stimulates osteoclast 
progenitor differentiation, mainly by enhancing their 
responsiveness to RANKL. RANKL drives both normal 
and pathophysiological osteoclast formation [17] but 
melphalan caused little or no increase in RANKL levels 
in bone or osteoblasts. In contrast, melphalan had a 
number of effects on osteoclast progenitors. Firstly, 
mouse bone marrow formed more osteoclasts ex vivo 
suggesting that more osteoclast progenitors are present; 
this was supported by the increased CD11b+ cell numbers 
in bone marrow. Secondly, melphalan very strikingly and 
directly increased osteoclast formation in RANKL-treated 
progenitors. We studied cell stress in melphalan treated 
osteoclastic cultures and found that melphalan induced 
a CSR, similar to previous findings with heat shock 
protein 90 (HSP90) inhibitors [14, 15, 18]. Presumably, 
unlike HSP90 inhibitors, this was due to cytotoxicity 
(e.g., protein misfolding) rather than direct activation 
of heat shock factor 1 (HSF1), the key transcription 
factor for CSR. CSR blockade by KNK437 rescued 
the stimulating effect on osteoclasts without affecting 
baseline RANKL-elicited osteoclast formation. MITF 
protein levels, critical for osteoclast gene expression, 
were also elevated by melphalan treatment, despite other 
critical RANKL-elicited factors such as NFATc1 being 
unaffected. MITF may be CSR-inducible [19] although to 
date we have yet to find strong evidence that stimulating 
a CSR directly increases MITF mRNA levels in BMM; 
this may suggest post-transcriptional influences of CSRs 
such as MITF protein stabilisation. To investigate the 
possible consequence of elevated MITF levels we studied 
melphalan effects on transcriptional targets of MITF. 
These include Dc-stamp which with Oc-stamp critically 
drives osteoclast cell fusion, a distinctive feature of 
osteoclasts that increases their resorption pit depth [20, 
21]. mRNA levels of both Dc-stamp and Oc-stamp were 
enhanced by melphalan. Consistent with this, melphalan 
enhanced cell fusion both in the presence and absence of 
RANKL. Thus, melphalan has three effects on osteoclast 
progenitors that increase their response to RANKL, which 
may be functionally linked: activation of CSR, increased 
MITF expression and enhanced cell fusion. Together 
these provide a strong mechanistic basis to explain the 
effects of melphalan on bone. These data also suggest that 
osteoclastic effects of melphalan reported here might also 
be observed with other cytotoxic drugs that induce a CSR 
in macrophage/osteoclast lineage cells.
The discovery that melphalan increases osteoclastic 
bone resorption has a number of important implications. 
First, the increased osteolysis induced by treatment may 
Figure 6: Diagram summarizing the positive effects of melphalan on osteoclast formation in this study. Melphalan 
slightly increased RANKL expression in osteoblastic stromal cells (dotted line); enhanced osteoclast progenitor numbers in vivo; increased 
differentiation in vitro at least partly in a cell stress dependent manner; enhanced MITF levels in osteoclast progenitors; and increased cell 
fusion possibly through increased Dc- and Oc-stamp levels. Increased osteoclast numbers seen both in vitro and in vivo with mephalan 
treatment can result in increased bone resorption and thus may potentially also enhance growth of tumor cells or activation of dormant 
tumors.
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compound the bone loss caused by myeloma growth 
in the skeleton. This could further increase the risk of 
pathological fracture that is already prevalent in this 
disease. Secondly, the process of bone resorption itself 
is known to release growth factors from bone matrix, 
including TGFβ, which can promote tumor growth in 
the skeleton and may indirectly effect the behavior of 
myeloma cells in bone. Finally, the bone resorption caused 
by melphalan treatment could disrupt the myeloma niches 
on the endosteal bone surface that maintain myeloma 
cells in a dormant state [4, 22]. In support of this we have 
recently demonstrated that osteoclasts, and processes 
that switch on bone turnover, reactivate dormant tumor 
cells in the skeleton and can increase tumor growth in 
bone [5]. However, the reactivation of dormant tumor 
cells in bone may provide a therapeutic benefit since their 
subsequent proliferation may render them susceptible to 
chemotherapy-related cytotoxicity [4].
Thus, in summary, we have identified pro-osteolytic 
effects of melphalan treatment and identified a number 
of molecular mechanisms that maybe responsible for the 
increase in osteoclastic resorption (Figure 6). These could 
have important implications for their use in the treatment 
of patients with myeloma. As a consequence, existing anti-
osteolytic therapies such as bisphosphonates should be 
considered alongside melphalan treatment in order to prevent 
the negative effects of melphalan treatment on the skeleton.
MATERIALS AND METHODS
Reagents and antibodies
Recombinant murine soluble RANKL 
(RANKL158-316–GST fusion protein) was obtained from 
the Oriental Yeast Co. (Tokyo, Japan) and human M-CSF 
from Sino Biological Inc. (Beijing, P.R. China). L-cell 
conditioned media (LCM; a source of secreted murine 
M-CSF) was prepared as previously described [23]. HSP 
inhibitor KNK437 were obtained from Sigma-Aldrich 
(St Louis, MO). Anti-MITF antibody (C5; cat. no. 
ab12039) was purchased from Abcam (Cambridge, MA). 
Anti-NFATc1 (cat. no. 556602) was purchased from BD 
Pharmingen (Franklin Lakes, NJ). Anti-HSP70 (HSPA1A) 
antibody (cat. no. ADI-SPA-812) was purchased from 
Enzo Life Sciences (San Diego, CA) and anti-β-actin 
was obtained from Cell Signaling Technology (Danvers, 
MA). IgG HRP-conjugated secondary antibodies for 
immunoblotting were purchased from Thermo Fisher 
(Scoresby, Victoria, Australia). 1,25 dihydroxyvitamin D3 
(1,25-D3) was obtained from the Wako Pure Chemical 
Co. (Tokyo, Japan). TRAP histochemical staining, fast 
red violet LB Salt, naphthol AS-MX phosphate and 
dimethylformamaide were purchased from Sigma-Aldrich 
(Castle Hill, New South Wales, Australia). All other 
reagent grade chemicals were supplied by Sigma-Aldrich 
unless noted.
Animals
8-week-old male C57BL/Kalwrij mice were treated 
with melphalan (Sigma-Aldrich, 5mg/kg) or vehicle for 3 
days (injected intraperitoneally on days 0 and 3), 7 days 
and 14 days (injected intraperitoneally 3 times a week). 
Mice were obtained from Australian BioResources (Moss 
Vale, New South Wales, Australia) and maintained at the 
Garvan Institute facilities. Procedures were approved 
by the Garvan Institute / St Vincent’s Hospital Animal 
Ethics Committee in accordance with New South Wales 
(Australia) State Government legislation.
Cell lines, cell culture and chemicals
L Cells and RAW264.7 cells were obtained from the 
American Type Culture Collection (ATCC; Manassas, VA) 
and maintained in minimal essential medium-ɑ (MEM) 
containing 10% fetal bovine serum (FBS), 50 units/mL 
penicillin, 50 mg/mL streptomycin, glutamax supplement 
and HEPES (all above reagents supplied by Thermo Fisher 
Scientific). All culture assays utilized this medium (MEM/
FBS) unless noted. Primary bone marrow cells for culture 
were immediately isolated from 6 to 12 week old mice by 
flushing the bone marrow cavity of the long bones with 
phosphate buffered saline (PBS). Primary BMM cultures 
were maintained in 30% L-cell conditioned media to 
induce BMM proliferation. BMSCs were generated from 
primary murine bone marrow cells flushed from bisected 
long bones of mice and maintained in MEM supplemented 
with 20% FBS. All cells were maintained in a 37°C 
incubator in a humidified atmosphere containing 5% CO2.
Micro-computed tomography (microCT) of the 
femur
Bone structure was analyzed using a Skyscan Model 
1172 microCT scanner (Bruker, Billerica, MA) at 50 kV, 
200 mA with a 0.5-mm aluminium filter using a pixel size 
of 4.3 mm. Images were captured every 0.4 ° through 
180 °, reconstructed and analyzed using NRecon and 
CTAn software (Bruker). Three-dimensional models and 
tomographic visualization were created using the Drishti-2 
software tool (https://code.google.com/p/drishti-2/) [24].
Histomorphometric analysis of the femur
Femora were fixed in 4% paraformaldehyde, 
decalcified in EDTA, embedded in paraffin and 3μm 
microtome sections (parasagittal plane) cut, dewaxed, 
reacted for TRAP and counterstained with Mayer’s 
hematoxylin (Sigma-Aldrich). Osteoclast number (Oc.N./
BS), and osteoclast surface (Oc.S/BS) were examined 
in two regions of the bone, the growth plate/primary 
spongiosa and in mature trabecular bone. For the latter, 
a region of interest 200 × 200 μm2 located 0.4mm below 
the distal growth plate was employed. These analyses 
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were performed using Osteomeasure histomorphometry 
software (Osteometrics, Atlanta, GA) [25].
FACS analysis
Bone marrow cells flushed from long bones were 
syringed five times through a 23-G needle and filtered 
through a 100μm nylon cell strainer. Red blood cells 
were lysed with 0.15 M NH4Cl. Cells were resuspended 
in PBS and filtered through a 70μm strainer. Samples 
were incubated with Fixable Viability Dye eFluor780 
(eBioscience, San Diego, CA) and Fc receptors were 
blocked with anti-mouse CD16/CD32 (Biolegend, 
San Diego, CA) at a dilution of 1:100. Cells were then 
incubated with anti-mouse CD115 APC, anti-mouse 
CD11b PERCP-Cy5.5, anti-mouse B220 Pe-Cy7, anti-
mouse CD11c PE, and anti-mouse Gr-1 Brilliant Violet 
421 (BioLegend) at a dilution of 1:100 in PBS/2% FBS. 
Samples were acquired on a FACSCanto II or LSR II 
SORP (BD Biosciences, San Jose, CA). Analysis was 
performed with FlowJo software (Tree Star, Ashland, OR).
Osteoclast differentiation assays
Osteoclasts were generated from primary BMCs 
flushed from mouse long bones resuspended in MEM/
FBS then added (105 cells/well) to 6mm diameter culture 
wells. These were stimulated with 20 ng/ml RANKL, plus 
25 ng/mL macrophage colony-stimulating factor (M-CSF), 
and melphalan, KNK437 or vehicle. Osteoclasts were 
also generated from RAW264.7 cells (5 x 103 per well) 
in 6mm diameter culture wells in MEM/FBS as above 
but without M-CSF. For BMC and RAW264.7 osteoclast 
cultures medium and agents were replaced at day 3, and 
on day 6 cultures were fixed with 4% paraformaldehyde 
and histochemically stained for TRAP using a pH 5 
phosphate buffered solution containing potassium tartrate, 
fast red violet LB salt and naphthol AS-MX phosphate 
as previously described [26]. TRAP-positive MNCs 
containing 3 or more nuclei were counted as osteoclasts 
and quantified by inverted light microscopy.
mRNA expression analysis with qRT-PCR
RNA was extracted from cells using Isolate II RNA 
mini kit (Bioline, Alexandria, NSW, Australia) according 
to manufacturer’s instructions. RNA (up to 2 μg) was 
treated to remove genomic DNA with 1 unit of DNase I 
(New England Biolabs, Beverly, MA) in 10 μL, incubated at 
37°C for 10 minutes then DNase inactivated at 75°C. cDNA 
was synthesized from DNase-treated RNA using a Tetro 
cDNA synthesis kit (Bioline) according to manufacturer’s 
instructions. The oligonucleotide primers employed in these 
analyses are listed in Supplementary Table 1. Samples were 
analyzed in duplicate using a qPCR mix containing 25-50 
ng cDNA, 1x iTAQ Sybr Green PCR master mix (Biorad) 
and 0.2 μM of each primer in a total volume of 10 μL. 
qPCR reactions were run on ABI Quantstudio7 (Thermo 
Fisher Scientific) with the following conditions: 10 mins of 
denaturation at 95ºC; 40 cycles of: 95ºC (15s), 60ºC (60s). 
To discriminate primer specific amplicon from primer 
dimers or unspecific PCR products, we also performed melt 
curve analysis with the following conditions: 95ºC (15s), 
60ºC (60s), 95ºC (15s). Comparative (delta-CT) values 
were calculated using Gus as a housekeeping gene, and 
expressed as relative to the vehicle control.
Luciferase reporter assays
RAW264.7 cell lines stably transfected with a G418-
selected construct that express firefly luciferase driven by 
promoters containing either NFkB- or an NFAT-response 
element-containing promoters (NFkB-RAW and NFAT-
RAW cells, respectively) were employed in reporter 
assays as previously described [27]. Briefly, reporter cells 
were seeded (4x104 cells/6mm diameter culture well) in 
MEM/FBS, incubated overnight, treatments added in 
triplicate wells over 24 h then lysed with Passive Lysis 
Buffer (Promega, Madison, WI) for 24 h at 4°C. Signal 
was measured using firefly luciferase substrate (Promega) 
as per manufacturer’s instruction using a Clariostar 
multifunctional microplate reader (BMG Labtech).
Western blot analysis
Western blot analysis was performed as previously 
described [18]. Briefly, cell lysates were generated using 
modified RIPA buffer (50 mM Tris-HCl (pH 7.4), 1% 
NP40, 0.25% Na deoxycholate, 150mM NaCl) containing 
phosphatase/protease inhibitor cocktail (Sigma-Aldrich), 
sonicated and centrifuged. Protein concentrations were 
determined by BCA protein assay as per manufacturer’s 
instructions (Thermo Fisher Scientific). Cell lysates were 
run on Criterion 4-20% Tris-Glycine gradient SDS-page 
electrophoresis gels (Biorad) with Tris-SDS running buffer 
under reducing conditions and transferred to Immobilon-P 
polyvinylidene difluoride (PVDF) membranes (Biorad). 
Membranes were blocked by incubation for 1 h in 3% 
skimmed milk powder (Diploma brand; Fonterra, Mount 
Waverley, Victoria, Australia) dissolved in TBS solution 
containing 0.1% Tween20 detergent (TBST); membranes 
were then incubated overnight at 4oC with appropriate primary 
antibodies in TBST/milk. Western blot signal detection 
was achieved by incubation with appropriate horseradish 
peroxidase (HRP) conjugated secondary antibodies specific for 
the primary antibody immunoglobulin species and visualized 
by ECL detection system (Supersignal West Pico; Thermo 
Fisher Scientific) according to the manufacturer’s instructions. 
Blots were then imaged with Vilber Lourmat Fusion Fx 
(Marne-la-Vallée, France) and intensity of bands (normalized 
to loading control) quantified with ImageJ software (https://
imagej.nih.gov/ij/docs/index.html).
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Statistical analysis
Data was analyzed using Prism 6 software 
(version 6.07; GraphPad, San Diego, CA) and statistical 
significance determined using unpaired t-test and one- and 
two-way comparisons using ANOVA and Bonferroni’s 
post hoc test for multiple comparisons as indicated. 
Quantitative in vivo data is presented as mean ± standard 
deviation; in vitro data is presented as mean ± SEM 
of three or more pooled independent experiments as 
specified, and significance is represented graphically by 
*p< 0.05, **p<0.01 and ***p<0.001 relative to controls.
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